163 related articles for article (PubMed ID: 32373232)
1. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
Boot A; Jiang N; Rozen SG
Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
4. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
5. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
[TBL] [Abstract][Full Text] [Related]
6. Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs.
Yang HY; Yang CC; Wu CY; Wang LJ; Lu KL
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261684
[TBL] [Abstract][Full Text] [Related]
7. Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium.
Chen CH; Grollman AP; Huang CY; Shun CT; Sidorenko VS; Hashimoto K; Moriya M; Turesky RJ; Yun BH; Tsai K; Wu S; Chuang PY; Tang CH; Yang WH; Tzai TS; Tsai YS; Dickman KG; Pu YS
Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):317-325. PubMed ID: 33277322
[TBL] [Abstract][Full Text] [Related]
8. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
Dickman KG; Chen CH; Grollman AP; Pu YS
World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
[TBL] [Abstract][Full Text] [Related]
9. Macroscopic somatic clonal expansion in morphologically normal human urothelium.
Li R; Du Y; Chen Z; Xu D; Lin T; Jin S; Wang G; Liu Z; Lu M; Chen X; Xu T; Bai F
Science; 2020 Oct; 370(6512):82-89. PubMed ID: 33004515
[TBL] [Abstract][Full Text] [Related]
10. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
11. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.
Xiao J; Zhu X; Hao GY; Zhu YC; Hou HJ; Zhang J; Ma LL; Tian Y; Zhang YH
Transplant Proc; 2011 Dec; 43(10):3751-4. PubMed ID: 22172840
[TBL] [Abstract][Full Text] [Related]
12. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway.
Chen IH; Luo HL; Su YL; Huang CC; Chiang PH; Yu CC; Lee NL; Lin JJ; Sung MT
Molecules; 2019 Oct; 24(20):. PubMed ID: 31619002
[TBL] [Abstract][Full Text] [Related]
13. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.
Lemy A; Wissing KM; Rorive S; Zlotta A; Roumeguere T; Muniz Martinez MC; Decaestecker C; Salmon I; Abramowicz D; Vanherweghem JL; Nortier J
Am J Kidney Dis; 2008 Mar; 51(3):471-7. PubMed ID: 18295063
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcome of Kidney Recipients Transplanted for Aristolochic Acid Nephropathy.
Kanaan N; Hassoun Z; Raggi C; Jadoul M; Mourad M; De Meyer M; Aydin S; Schmeiser HH; Cosyns JP; Goffin E
Transplantation; 2016 Feb; 100(2):416-21. PubMed ID: 26457602
[TBL] [Abstract][Full Text] [Related]
15. Aristolochic acid-associated urothelial cancer in Taiwan.
Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
[TBL] [Abstract][Full Text] [Related]
16. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy.
Shan H; Tian W; Hong Y; Xu B; Wang C; Yu B; Wang X
BMC Complement Med Ther; 2020 Jun; 20(1):166. PubMed ID: 32493345
[TBL] [Abstract][Full Text] [Related]
18. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.
Ng AWT; Poon SL; Huang MN; Lim JQ; Boot A; Yu W; Suzuki Y; Thangaraju S; Ng CCY; Tan P; Pang ST; Huang HY; Yu MC; Lee PH; Hsieh SY; Chang AY; Teh BT; Rozen SG
Sci Transl Med; 2017 Oct; 9(412):. PubMed ID: 29046434
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
Aydin S; Ambroise J; Cosyns JP; Gala JL
Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
[TBL] [Abstract][Full Text] [Related]
20. A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.
Odell AF; Odell LR; Askham JM; Alogheli H; Ponnambalam S; Hollstein M
J Biol Chem; 2013 Jun; 288(23):16704-16714. PubMed ID: 23612969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
